Price Target Changed • Jun 02
Price target increased by 11% to ₩89,000 Up from ₩80,000, the current price target is an average from 2 analysts. New target price is 64% above last closing price of ₩54,400. Stock is down 14% over the past year. The company is forecast to post earnings per share of ₩7,566 for next year compared to ₩4,725 last year. Valuation Update With 7 Day Price Move • May 20
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₩61,900, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total returns to shareholders of 19% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩54,710 per share. Major Estimate Revision • Apr 17
Consensus EPS estimates increase by 20%, revenue downgraded The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast fell from ₩215.4m to ₩195.4m. EPS estimate rose from ₩5,898 to ₩7,053. Net income forecast to grow 26% next year vs 64% growth forecast for Medical Equipment industry in South Korea. Consensus price target up from ₩80,000 to ₩85,000. Share price rose 27% to ₩65,500 over the past week. Buy Or Sell Opportunity • Apr 16
Now 27% overvalued after recent price rise Over the last 90 days, the stock has risen 44% to ₩63,400. The fair value is estimated to be ₩50,022, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last 3 years. Earnings per share has grown by 25%. Revenue is forecast to grow by 47% in 2 years. Earnings are forecast to grow by 50% in the next 2 years. Valuation Update With 7 Day Price Move • Apr 13
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₩57,300, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 26% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩50,150 per share. Buy Or Sell Opportunity • Mar 23
Now 20% overvalued Over the last 90 days, the stock has fallen 3.6% to ₩47,050. The fair value is estimated to be ₩39,179, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 30% over the last 3 years. Earnings per share has grown by 30%. Revenue is forecast to grow by 32% in 2 years. Earnings are forecast to grow by 27% in the next 2 years. Buy Or Sell Opportunity • Mar 05
Now 30% overvalued after recent price rise Over the last 90 days, the stock has risen 3.9% to ₩51,000. The fair value is estimated to be ₩39,146, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 30% over the last 3 years. Earnings per share has grown by 30%. Revenue is forecast to grow by 32% in 2 years. Earnings are forecast to grow by 27% in the next 2 years. Valuation Update With 7 Day Price Move • Mar 04
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₩45,550, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 7.9% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩39,227 per share. Major Estimate Revision • Feb 27
Consensus EPS estimates fall by 15% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from ₩188.6m to ₩170.2m. EPS estimate also fell from ₩6,017 per share to ₩5,110 per share. Net income forecast to grow 12% next year vs 28% growth forecast for Medical Equipment industry in South Korea. Consensus price target of ₩80,000 unchanged from last update. Share price was steady at ₩54,700 over the past week. Announcement • Feb 25
T&L Co., Ltd., Annual General Meeting, Mar 26, 2026 T&L Co., Ltd., Annual General Meeting, Mar 26, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 70-17, wonam-ro, wongok-myeon, gyeonggi-do, anseong South Korea Valuation Update With 7 Day Price Move • Jan 29
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₩52,300, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 11x in the Medical Equipment industry in South Korea. Total returns to shareholders of 43% over the past three years. Upcoming Dividend • Dec 22
Upcoming dividend of ₩750 per share Eligible shareholders must have bought the stock before 29 December 2025. Payment date: 10 April 2026. Payout ratio is a comfortable 14% and this is well supported by cash flows. Trailing yield: 1.6%. Lower than top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (1.1%). Declared Dividend • Nov 08
Dividend of ₩750 announced Dividend of ₩750 is the same as last year. Ex-date: 29th December 2025 Payment date: 10th April 2026 Dividend yield will be 1.7%, which is about the same as the industry average. Sustainability & Growth Dividend is well covered by both earnings (13% earnings payout ratio) and cash flows (17% cash payout ratio). The dividend has increased by an average of 17% per year over the past 4 years and payments have been stable during that time. EPS is expected to grow by 42% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Announcement • Nov 07
T&L Co., Ltd. announces Annual dividend, payable on April 10, 2026 T&L Co., Ltd. announced Annual dividend of KRW 750.0000 per share payable on April 10, 2026, ex-date on December 29, 2025 and record date on December 31, 2025. Announcement • Sep 23
T&L Co., Ltd. (KOSDAQ:A340570) announces an Equity Buyback for KRW 10,000 million worth of its shares. T&L Co., Ltd. (KOSDAQ:A340570) announces a share repurchase program. Under the program, the company will repurchase up to KRW 10,000 million worth of its shares pursuant to a contract with Korea Investment & Securities Co., Ltd. The purpose of the share repurchase is stock price stability and shareholder value enhancement. The repurchase program will expire on September 23, 2026. Major Estimate Revision • Aug 23
Consensus revenue estimates decrease by 13% The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from ₩218.8m to ₩191.3m. EPS estimate unchanged from ₩5,926 per share at last update. Medical Equipment industry in South Korea expected to see average net income growth of 31% next year. Consensus price target down from ₩99,000 to ₩80,000. Share price fell 11% to ₩53,000 over the past week. Reported Earnings • Mar 21
Full year 2024 earnings: EPS exceeds analyst expectations Full year 2024 results: EPS: ₩5,749 (up from ₩3,399 in FY 2023). Revenue: ₩174.9b (up 52% from FY 2023). Net income: ₩46.4b (up 69% from FY 2023). Profit margin: 27% (up from 24% in FY 2023). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 3.2%. Revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 23% growth forecast for the Medical Equipment industry in South Korea. Over the last 3 years on average, earnings per share has increased by 27% per year whereas the company’s share price has increased by 23% per year. Announcement • Feb 27
T&L Co., Ltd., Annual General Meeting, Mar 25, 2025 T&L Co., Ltd., Annual General Meeting, Mar 25, 2025, at 10:00 Tokyo Standard Time. Location: seminar room, 70-17, wonam-ro, wongok-myeon, gyeonggi-do, anseong South Korea Valuation Update With 7 Day Price Move • Jan 17
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩77,100, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 11x in the Medical Equipment industry in South Korea. Total returns to shareholders of 96% over the past three years. Upcoming Dividend • Dec 20
Upcoming dividend of ₩550 per share Eligible shareholders must have bought the stock before 27 December 2024. Payment date: 11 April 2025. Payout ratio is a comfortable 11% and this is well supported by cash flows. Trailing yield: 0.9%. Lower than top quartile of South Korean dividend payers (3.9%). Lower than average of industry peers (1.4%). Reported Earnings • Nov 20
Third quarter 2024 earnings released: EPS: ₩1,641 (vs ₩948 in 3Q 2023) Third quarter 2024 results: EPS: ₩1,641 (up from ₩948 in 3Q 2023). Revenue: ₩48.7b (up 62% from 3Q 2023). Net income: ₩13.2b (up 73% from 3Q 2023). Profit margin: 27% (up from 26% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Medical Equipment industry in South Korea. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Aug 19
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₩73,000, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 11x in the Medical Equipment industry in South Korea. Total returns to shareholders of 72% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩51,502 per share. Major Estimate Revision • Aug 17
Consensus EPS estimates increase by 12% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from ₩164.6m to ₩173.1m. EPS estimate increased from ₩5,234 to ₩5,853 per share. Net income forecast to grow 86% next year vs 69% growth forecast for Medical Equipment industry in South Korea. Consensus price target of ₩90,500 unchanged from last update. Share price rose 15% to ₩68,300 over the past week. Buy Or Sell Opportunity • Jul 29
Now 21% overvalued The stock has been flat over the last 90 days, currently trading at ₩60,100. The fair value is estimated to be ₩49,567, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 28% over the last 3 years. Earnings per share has grown by 22%. Revenue is forecast to grow by 78% in 2 years. Earnings are forecast to grow by 107% in the next 2 years. Buy Or Sell Opportunity • Jun 12
Now 24% overvalued after recent price rise Over the last 90 days, the stock has risen 31% to ₩62,100. The fair value is estimated to be ₩50,159, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 28% over the last 3 years. Earnings per share has grown by 22%. Revenue is forecast to grow by 59% in 2 years. Earnings are forecast to grow by 76% in the next 2 years. Valuation Update With 7 Day Price Move • Jun 07
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₩54,200, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 62% over the past three years. Valuation Update With 7 Day Price Move • May 16
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to ₩70,800, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 154% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩117,394 per share. Reported Earnings • Mar 21
Full year 2023 earnings: EPS misses analyst expectations Full year 2023 results: EPS: ₩3,399 (up from ₩2,602 in FY 2022). Revenue: ₩115.5b (up 42% from FY 2022). Net income: ₩27.4b (up 30% from FY 2022). Profit margin: 24% (down from 26% in FY 2022). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 10%. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Medical Equipment industry in South Korea. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has increased by 35% per year, which means it is tracking significantly ahead of earnings growth. Price Target Changed • Mar 21
Price target increased by 7.9% to ₩61,500 Up from ₩57,000, the current price target is an average from 2 analysts. New target price is 19% above last closing price of ₩51,800. Stock is up 14% over the past year. The company is forecast to post earnings per share of ₩3,779 for next year compared to ₩2,602 last year. Major Estimate Revision • Mar 21
Consensus EPS estimates increase by 12% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from ₩131.0m to ₩136.4m. EPS estimate increased from ₩3,872 to ₩4,340 per share. Net income forecast to grow 14% next year vs 36% growth forecast for Medical Equipment industry in South Korea. Consensus price target up from ₩57,000 to ₩61,500. Share price rose 9.6% to ₩51,800 over the past week. Valuation Update With 7 Day Price Move • Jan 09
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₩44,450, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 16x in the Medical Equipment industry in South Korea. Total returns to shareholders of 109% over the past three years. Upcoming Dividend • Dec 20
Upcoming dividend of ₩450 per share at 1.1% yield Eligible shareholders must have bought the stock before 27 December 2023. Payment date: 11 April 2024. Payout ratio is a comfortable 12% and this is well supported by cash flows. Trailing yield: 1.1%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (1.6%). Price Target Changed • Apr 11
Price target increased by 11% to ₩59,500 Up from ₩53,500, the current price target is an average from 2 analysts. New target price is 25% above last closing price of ₩47,700. Stock is up 5.4% over the past year. The company is forecast to post earnings per share of ₩4,170 for next year compared to ₩2,602 last year. Major Estimate Revision • Jan 20
Consensus EPS estimates fall by 16% The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from ₩88.8m to ₩82.4m. EPS estimate also fell from ₩3,187 per share to ₩2,692 per share. Net income forecast to grow 32% next year vs 30% growth forecast for Medical Equipment industry in South Korea. Consensus price target broadly unchanged at ₩54,500. Share price rose 7.3% to ₩39,700 over the past week. Upcoming Dividend • Dec 21
Upcoming dividend of ₩400 per share Eligible shareholders must have bought the stock before 28 December 2022. Payment date: 05 April 2023. Payout ratio is a comfortable 15% and this is well supported by cash flows. Trailing yield: 1.1%. Lower than top quartile of South Korean dividend payers (3.3%). Lower than average of industry peers (1.8%). Reported Earnings • Nov 17
Third quarter 2022 earnings released: EPS: ₩677 (vs ₩758 in 3Q 2021) Third quarter 2022 results: EPS: ₩677 (down from ₩758 in 3Q 2021). Revenue: ₩20.5b (up 12% from 3Q 2021). Net income: ₩5.50b (down 11% from 3Q 2021). Profit margin: 27% (down from 34% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Medical Equipment industry in South Korea. Valuation Update With 7 Day Price Move • Sep 16
Investor sentiment improved over the past week After last week's 19% share price gain to ₩40,500, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total loss to shareholders of 29% over the past year. Major Estimate Revision • Jul 29
Consensus EPS estimates increase by 14% The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from ₩86.4m to ₩89.1m. EPS estimate increased from ₩2,916 to ₩3,320 per share. Net income forecast to grow 36% next year vs 22% growth forecast for Medical Equipment industry in South Korea. Consensus price target down from ₩56,500 to ₩51,500. Share price rose 4.6% to ₩35,600 over the past week. Price Target Changed • Jul 28
Price target decreased to ₩51,000 Down from ₩60,000, the current price target is an average from 2 analysts. New target price is 41% above last closing price of ₩36,200. Stock is down 4.4% over the past year. The company is forecast to post earnings per share of ₩3,364 for next year compared to ₩2,410 last year. Valuation Update With 7 Day Price Move • Jun 22
Investor sentiment deteriorated over the past week After last week's 15% share price decline to ₩31,100, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 11x in the Medical Equipment industry in South Korea. Total loss to shareholders of 25% over the past year. Announcement • Jun 16
T&L Co., Ltd. (KOSDAQ:A340570) announces an Equity Buyback for KRW 10,000 million worth of its shares. T&L Co., Ltd. (KOSDAQ:A340570) announces a share repurchase program. Under the program, the company will repurchase up to KRW 10,000 million worth of its shares pursuant to a contract with Korea Investment & Securities Co., Ltd. The purpose of the share repurchase is stock price stability and shareholder value enhancement. The repurchase program will expire on December 14, 2022. As of June 14, 2022, the company had no shares within scope available for dividend and had no shares in treasury through other repurchase. Price Target Changed • Apr 27
Price target decreased to ₩60,000 Down from ₩80,000, the current price target is an average from 2 analysts. New target price is 51% above last closing price of ₩39,850. Stock is up 28% over the past year. The company is forecast to post earnings per share of ₩2,989 for next year compared to ₩2,410 last year. Upcoming Dividend • Dec 22
Inaugural dividend of ₩200 per share Eligible shareholders must have bought the stock before 29 December 2021. Payment date: 11 April 2022. The company is not currently making a profit but it is cash flow positive. This is the first dividend for T&L since going public. The average dividend yield among industry peers is 0.7%. Valuation Update With 7 Day Price Move • Dec 06
Investor sentiment improved over the past week After last week's 15% share price gain to ₩43,750, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 119% over the past year. Valuation Update With 7 Day Price Move • Sep 16
Investor sentiment improved over the past week After last week's 19% share price gain to ₩58,300, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 15x in the Medical Equipment industry in South Korea. Simply Wall St's valuation model estimates the intrinsic value at ₩107,730 per share. Valuation Update With 7 Day Price Move • Aug 26
Investor sentiment improved over the past week After last week's 22% share price gain to ₩51,000, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 17x in the Medical Equipment industry in South Korea. Valuation Update With 7 Day Price Move • Aug 05
Investor sentiment improved over the past week After last week's 18% share price gain to ₩46,500, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 15x in the Medical Equipment industry in South Korea. Valuation Update With 7 Day Price Move • Jun 14
Investor sentiment improved over the past week After last week's 16% share price gain to ₩69,500, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 17x in the Medical Equipment industry in South Korea. Valuation Update With 7 Day Price Move • Mar 31
Investor sentiment improved over the past week After last week's 15% share price gain to ₩47,200, the stock trades at a trailing P/E ratio of 15.6x. Average forward P/E is 12x in the Chemicals industry in South Korea. Is New 90 Day High Low • Feb 23
New 90-day low: ₩39,050 The company is down 28% from its price of ₩54,100 on 25 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 16% over the same period. Announcement • Feb 09
T&L Co., Ltd., Annual General Meeting, Mar 25, 2021 T&L Co., Ltd., Annual General Meeting, Mar 25, 2021, at 10:00 Korea Standard Time. Location: T&L Seminar Room, 70-17 Wonam-ro, Wongok-myeon, Anseong-si Gyeonggi-do South Korea Valuation Update With 7 Day Price Move • Jan 07
Investor sentiment improved over the past week After last week's 15% share price gain to ₩49,300, the stock is trading at a trailing P/E ratio of 20.3x, up from the previous P/E ratio of 17.6x. This compares to an average P/E of 16x in the Chemicals industry in South Korea. Valuation Update With 7 Day Price Move • Dec 04
Market pulls back on stock over the past week After last week's 19% share price decline to ₩41,750, the stock is trading at a trailing P/E ratio of 17.2x, down from the previous P/E ratio of 21.1x. This compares to an average P/E of 15x in the Chemicals industry in South Korea. Valuation Update With 7 Day Price Move • Dec 02
Market pulls back on stock over the past week After last week's 16% share price decline to ₩45,650, the stock is trading at a trailing P/E ratio of 18.8x, down from the previous P/E ratio of 22.2x. This compares to an average P/E of 15x in the Chemicals industry in South Korea. Valuation Update With 7 Day Price Move • Nov 30
Market pulls back on stock over the past week After last week's 18% share price decline to ₩48,450, the stock is trading at a trailing P/E ratio of 19.9x, down from the previous P/E ratio of 24.4x. This compares to an average P/E of 15x in the Chemicals industry in South Korea. 